The Nvidia Killer is Here

Sponsored

Artificial intelligence could have already made you a millionaire… Because back in 2013, researchers from Stanford University built the “world's largest virtual brain” with Nvidia chips. This single event marked the beginning of the chipmaker's reign as the “King of AI.” You could've raked in 12,035% gains had you bought Nvidia shares when this story became public. That's enough to turn a $9,000 stake into more than $1 million. But there's no reason to beat yourself up for missing out on this life-changing opportunity. Today you have a second shot at six- or even seven-figure gains. Because there's a new player in town… One that's set to dethrone Nvidia. This off-the-radar company from California is about to release an AI chip that's superior to Nvidia's technology. I'm talking about a 100x performance boost. Access to this kind of chip is still highly restricted. The U.S. Air Force is one elite client that was allowed to use it early. But soon it will be available to the mainstream. And if you position yourself BEFORE this chip reaches the mass market, you could turn every $1 into $120… Just like early Nvidia investors did. I just published a brand-new presentation on this unique opportunity. Access is instant and free. Get the full story here while there's still time.

---

Medtronic (MDT), a titan in the biotech realm, has not just been making waves but causing tsunamis with its stellar financial performances and groundbreaking strategic leaps forward.

And it just crushed its most recent earnings report.

As we pull back the curtain on this industry behemoth, we uncover a tapestry of innovation, resilience, and ambition.

Dive with us into this report, where we unravel all the reasons that make Medtronic not just an attractive investment but a thrilling voyage into the future of biotech.

Key Financial Highlights

Revenue Growth: Medtronic reported a Q1 worldwide revenue of $7.702 billion, marking a 4.5% increase as reported and a 6.0% organic growth. This growth reflects the company's strength across various businesses and geographies, underpinned by innovation and robust underlying fundamentals.

Earnings Per Share (EPS): While the GAAP diluted EPS of $0.59 saw a 16% decrease, the non-GAAP diluted EPS of $1.20 increased by 6%. This growth, despite the unfavorable impact from foreign currency translation, indicates the company's ability to maintain profitability.

Guidance for FY24: Medtronic has raised its FY24 organic revenue growth guidance to 4.5% and increased its non-GAAP EPS guidance range to $5.08 to $5.16, reflecting confidence in its future performance.

Operational Highlights

Product Launches: Medtronic has commenced U.S. launches of the MiniMed™ 780G system with Guardian™ 4 sensor in the Diabetes segment and the Micra™ AV2 and Micra™ VR2 leadless pacemakers in the Cardiovascular segment. These launches signify the company's commitment to innovation and addressing patient needs.

Cardiovascular Portfolio: This segment saw a revenue of $2.850 billion, a 5.5% increase as reported, driven by growth in Defibrillation Solutions, Cardiovascular Diagnostics, and Cardiac Pacing Therapies.

Neuroscience Portfolio: With a revenue of $2.219 billion, this segment witnessed growth in Spine & Biologics, ENT, and Brain Modulation, highlighting the company's diversified strength.

Medical Surgical Portfolio: Reporting a revenue of $2.039 billion, this segment saw growth in Advanced Surgical Technologies and Patient Monitoring, emphasizing the company's broad-based capabilities.

Diabetes: The Diabetes segment reported a revenue of $578 million, a 6.8% increase, driven by the MiniMed™ 780G system's adoption and the strength of the Guardian™ 4 sensor.

Management's Perspective: Geoff Martha, Medtronic's chairman and CEO, expressed satisfaction with the company's strong start to the fiscal year, emphasizing the broad-based results across all segments. The company's focus on transformation aims to ensure sustainable growth and maximize shareholder value.

Conclusion

Medtronic's recent financial results, combined with its strategic advancements and management's optimistic outlook, make it a promising biotech stock for potential investors. The company's commitment to innovation, its diversified portfolio, and its ability to navigate challenges position it well for future growth. Investors seeking a robust biotech stock with a proven track record and a bright future should consider Medtronic plc as a top contender.

---

NASA and Bill Gates are ALL IN on this new technology

Sponsored

Elon Musk's rival space-faring company, NASA, just partnered up with this little known company… Why? Because this tiny company holds the key to a $7 Trillion Dollar revolution. Most mainstream investors have no idea this $7 Trillion Revolution is taking place… But while everyone else is distracted by AI, this new phenomenon is quietly taking the tech world by storm… Companies like Google, Intel, and Microsoft are SCRAMBLING to get ahead of it… Even Bill Gates is ALL-IN on this new innovation… “…It's as revolutionary as the personal computer, the Internet, and the mobile phone.” It's no wonder why NASA decided to partner up with the leading company in this silent revolution… >>Click here to discover the innovation that has NASA and Bill Gates so excited.

#1 AI stock trading for $3

Sponsored

AI is by far the biggest tech investing trend of 2024. But Ross Givens says the #1 artificial intelligence stock is NOT Microsoft, Google, Amazon or Apple. Nope – his research is pointing to a tiny, under-the-radar stock that's trading for just $3 right now… And could soon shoot to the moon, handing early investors a windfall. This company already has 98 registered patents for cutting-edge voice and sound recognition technology… And has lined up major partnerships with Honda, Netflix, Pandora, Mercedes Benz and many, many others. So if you missed out on Microsoft when it first went public back in 1986… This could be your shot at redemption. Click here now for the full details of this $3 stock that's set to rocket in the AI revolution…

---

Biogen (BIIB)

Biogen stands out as a leader in the biopharmaceutical industry with its focus on discovering, developing, and delivering innovative therapies for complex and serious diseases. The company has a diversified portfolio that includes treatments for multiple sclerosis (MS) and spinal muscular atrophy (SMA). Notably, Biogen introduced the first approved treatment for SMA, marking a significant milestone in the medical community. This broad portfolio positions Biogen as a resilient player in the biotech sector, making it a compelling investment opportunity.

Biogen's commitment to advancing its pipeline in specialized fields like neurology, neuropsychiatry, and immunology is noteworthy. The company is also co-developing treatments for Alzheimer's disease, a condition that has long eluded effective therapy. Biogen's robust internal R&D programs and strategic external collaborations further strengthen its position as a frontrunner in biotech innovation.

Recent developments indicate that Biogen is not afraid to make tough decisions for long-term gains. For instance, the company recently amended the Phase 2b LUMA study for BIIB122 to include a broader patient base, targeting both early-stage Parkinson’s disease and those with a specific genetic mutation. While they have paused or terminated some projects like BIIB093 and BIIB131 due to operational challenges or strategic considerations, this adaptability could be seen as a strength. It shows that the company is focused on prioritizing its resources effectively.

Despite a recent decrease in total revenue, Biogen's financials should be viewed in the context of its ongoing investments in R&D and strategic shifts. The company recorded close-out costs of approximately $13.2 million for BIIB093, which is a part of its broader financial strategy. Investors should consider the company's long-term potential and its ability to bounce back, given its history and diverse portfolio.

Biogen is also making strides in the biosimilars market, commercializing advanced biologics like BENEPALI, IMRALDI, and FLIXABI in Europe. The company is developing potential new biosimilar products, including BIIB800 and SB15, which could offer additional revenue streams in the future. This diversification into biosimilars adds another layer of resilience to Biogen's business model, making it a well-rounded investment choice in the biotech sector.

In summary, Biogen's innovative portfolio, cutting-edge R&D, strategic adaptability, financial resilience, and diversification into biosimilars make it one of the best biotech stocks to buy now.

Regeneron (REGN)

Regeneron Pharmaceuticals (REGN) has recently gained FDA approval for an 8-milligram dose of its vision loss drug, Eylea HD, a significant increase from the prior 2-milligram dose. This approval came earlier than anticipated, signaling a positive relationship with regulatory bodies. Eylea HD is designed to treat wet age-related macular degeneration and other vision-related conditions, and this new approval strengthens Regeneron's position in the market.

Financially, Eylea is a cornerstone for Regeneron, accounting for over half of the company's sales in 2022. The high-dose version is priced at $2,625 per vial, and projections for its sales are optimistic. Analyst Christopher Raymond from Piper Sandler anticipates Eylea sales to reach $6.2 billion in 2023, $6.75 billion in 2024, and $6.85 billion in 2025, indicating a strong revenue stream for the company.

The stock market has responded favorably to this news. REGN stock was trading at $821.26, marking a 1% increase in premarket trading following the FDA approval. Analysts are bullish on the stock; Hartaj Singh from Oppenheimer raised his target price to $1,050, indicating a potential 29% gain, while Brian Abrahams from RBC Capital Markets increased his target to $830. The stock is currently trading at a premium, at 18.9 times the expected earnings for the next 12 months, compared to its five-year average of 15.3 times.

In terms of competition, Eylea HD is set to go head-to-head with Novartis' Vabysmo. Despite a higher per-vial price for Eylea HD ($2,625) compared to Vabysmo ($2,190), the annual costs are closely aligned, making Eylea a competitive offering. This is particularly important as Eylea will soon face competition from lower-priced biosimilars, making the timing of the high-dose approval quite strategic.

In conclusion, Regeneron's recent FDA approval for a higher dose of Eylea HD, its strong financial outlook, and positive sentiments from Wall Street analysts make it a compelling biotech stock for investment. The company is well-positioned to maintain or even extend its market share in treatments for eye diseases, especially with the introduction of high-dose Eylea. This, combined with its competitive pricing and promising future outlook, positions Regeneron as a top biotech stock to consider.

---

Buy this $5 ASAP – before their next move

Sponsored

One Wall Street Veteran has been on a hot streak for the past several years… Spotting companies that delivered massive payouts: And now – he's revealing his #1 stock for 2024 – currently trading for less than $5. Click here to reveal the ticker

Source

The tide is turning in the fight against the coronavirus.

Two pharmaceutical companies, Pfizer, in partnership with BioNTech, and Moderna, have announced successful phase 3 trial results with efficacy rates above 90% — much higher than expected — and a number of other drug companies are on track to release late-stage results in the coming weeks. For Pfizer and Moderna, FDA approval is expected soon, and Dr. Anthony Fauci, the director of the National Institute for Allergy and Infectious Diseases, has said that healthcare workers could have access to a vaccine as soon as December, with the average American being able to get vaccinated by April if things go well.

Not surprisingly, that news has shaken the stock market. When Pfizer became the first company to announce successful Phase 3 results on Nov. 10, recovery stocks, along with the Dow Jones Industrial Average and the small-cap Russell 2000 index, got a big boost while the Nasdaq sank, a sign that investors were selling “stay-at-home” stocks like Zoom Video Communications (NASDAQ:ZM), Peloton Interactive (NASDAQ:PTON), and Wayfair (NYSE:W), among others, and rotating into stocks that will benefit from the economic reopening, like those in the travel, entertainment, and energy sectors.

As you can see from the chart below, all three of those stocks have fallen sharply since the Pfizer news came out, even as the S&P 500 has continued to gain.

Our #1 Biotech Stock for 2021

The trio of stay-at-home stocks have been big winners this year, but the market now seems to have other thoughts. Is it time to sell coronavirus stocks like Zoom, Peloton, and Wayfair? Let's take a look back at 2020 before examining what the future may hold.

A coronavirus boom

It's an understatement to say that Zoom, Peloton, and Wayfair have gotten a tailwind from the coronavirus pandemic. All three companies have experienced dramatic spikes in business that would not have happened without a crisis that's reshaped the way people communicate, exercise, and shop. These stocks have all experienced monster gains this year, as the chart below shows, driven by a temporary surge in revenue growth.

You can see from the chart below that revenue took off for all three of these companies once the pandemic struck in March.

The trends driving these companies — working from home for Zoom, working out from home for Peloton, and e-commerce combined with home improvement in the case of Wayfair — will remain strong for the duration of the pandemic, but we now know that the public health crisis that has significantly altered daily life in the U.S. will likely come to an end, and probably in just a few more months.

[SEE Also: Off the radar biotech expected to see massive growth in 2021]

The end is nigh

When the pandemic is over, we'll likely see an overwhelming return to the behavioral norms, a reversion to the mean. Americans will no longer be afraid of gathering together and potentially contracting a deadly virus. Offices will reopen and white-collar workers will return. Gyms and yoga studios will spring back to life along with the gym rats who have missed them, and shoppers will return to stores and spend at least some of their discretionary income on vacations and restaurants rather than home goods.

That means a post-coronavirus hangover is coming for all three of these stocks. They all have different business models and will deal with the aftermath of the pandemic differently, but they'll experience headwinds from the normalization of the economy, much as they got tailwinds from the pandemic. Still, they'll retain a good portion of the customers they gained during the crisis, but delivering growth on top of what's been a highly unusual year will be difficult, and these companies could see four quarters of weak results as they lap the skyrocketing growth of the pandemic era.

Is it time to sell?

All three of these stocks are leaders in their various sectors and there's no doubt the pandemic has only entrenched them further as the top dogs. Gone are the questions about whether Zoom has an edge over Skype, or whether Peloton is too expensive to go mainstream, or whether Wayfair can ever be profitable. Even factoring in the coming headwinds, these companies will have gotten an overwhelming net benefit from the public health crisis, which has greatly increased their customer base and brand awareness.

But the impending arrival of a vaccine means that there's now a cloud hanging over these stocks, and that's unlikely to go away. Valuations at all three of these stocks soared during the crisis, and it will take time for these companies to grow into those new price tags. This is especially true because their growth rates will soon decelerate, as much of the growth they would have experienced has been pulled forward. Netflix, another popular stay-at-home stock, has already experienced this phenomenon.

Still, over the long term, the future continues to look bright for these companies, and their growth rates should reaccelerate once the difficult year-over-year comparisons to the past few quarters have passed. Those future growth rates could return to near pre-crisis levels, which for Zoom and Peloton were very strong (in the high double digits). All three of these companies are leaders in fast-growing industries — videoconferencing, connected fitness, and online home furnishings, respectively — and those industries still have bright long-term prospects.

However, investors need to recognize that 2020 has been an anomaly, and these companies have been useful service providers during a crisis. They're selling umbrellas in a torrential downpour, but the storm will eventually pass.

People will still need and want the services that Zoom, Peloton, and Wayfair provide, but investors in these stocks should expect some significant volatility short term as these companies will soon be operating in a much different environment.

After months of fervent speculation surrounding “Battery Day,” the much-anticipated and hyped-up Tesla (NASDAQ: TSLA) event teased by Elon Musk for months, the market has been left, well, disappointed.

Tesla’s share price dropped ~8% on Wednesday, shedding roughly $30 billion in value from the automaker as investors came to grips with an underwhelming reality: Not only did Tesla not have anything truly groundbreaking up its sleeve, but it would take another two years to get what minimal improvements it was making into production.

Simply put, Tesla’s Battery Day was a major flop.

Now, there are a few reasons Tesla’s presentation ended up feeling so lackluster. One reason is simply that it did not meet the enormous expectations set up by the company and its fan base.

In an earnings call leading to the event, Elon Musk was rather colorful in his teaser statement saying, “Battery Day people. Wait until Battery Day. It's gonna blow your mind. It blows my mind, and I know it!”

And in response to a Teslerati.com story suggesting that Tesla’s battery announcement could be “more insane than expected,” Musk Tweeted out a comment saying, “It will be very insane.

Statements like these are entirely safe for Elon to put out there because they don’t say anything concrete. There are no specific claims involved, but it provides enough ammo for the die-hard bulls to speculate blue-sky scenarios. The narrative heading into this week was that whatever Tesla was about to announce was going to make the rest of the auto industry obsolete but this obviously did not happen.

Another reason for the resounding disappointment was the lack of any tangible evidence of Tesla’s new battery technology. Perhaps the company has decided to move away from live demonstrations after accidentally smashing the “bulletproof” windows of its Cybertruck, but whatever the reason, we were left with nothing but a slide deck.

As for what that slide deck showcased, Tesla plans to produce its own “tabless” batteries, which will ultimately increase range by 16% according to the company. This is a solid improvement, there’s no doubt, but it is nothing truly groundbreaking for the automotive industry.

Tesla also made a few more promises with no timelines attached. The company plans to build a new cathode plant and will eventually stop using cobalt in its cathodes. Tesla also dropped a $25,000 price tag as its next goal for affordable electric cars. The market can take that claim with a grain of salt, considering Tesla has yet to deliver on even a $35,000 EV. A bare-bones Model 3 currently still retails at $38,000.

Other than that, there wasn’t much for Tesla to boast about on Battery Day. We’re effectively looking at a 16% range increase by 2022 and some undefined promises about cost reductions. That’s it.

Meanwhile, battery technology continues to develop outside of Tesla’s own research and development arm, as the broader automotive industry aims to transition away from the combustion engine. Unfortunately for Musk, at least one of these developments now threatens to leapfrog Tesla and challenge its status as the de facto electric vehicle innovator.

Did Elon Poke the Bear?

Elon is known to occasionally put his foot in his mouth, a habit that has sparked public battles with the SEC and, more recently, with politicians like Bernie Sanders. One rivalry you might not be familiar with, though, is Elon’s beef with Bill Gates.

Throughout 2020, the two billionaires have traded barbs in various interviews and on social media. The disagreement seemed reached a peak earlier this year when Gates suggested we would need an alternative solution to electric vehicles for long-haul vehicles and opted for an all-electric Porsche Taycan. Musk seemed to take this personally and responded by saying that Gates has “no idea” what he’s talking about and claimed that his “conversations with Gates have been underwhelming.”

 

Gates has had his own slights to make about Elon, effectively telling him to stay in his lane on the COVID-19 issue and, more recently, saying that Elon Musk is no Steve Jobs. Clearly, the two tech moguls would like to take each other down a peg. As one might expect, there’s a lot of ego that comes with being the second and third richest people on the planet.

There may be more to these public jabs, though, than meets the eye. Behind the scenes, Bill Gates is funding a new battery technology company that has amassed 200 patent,s with the potential to make even Tesla look like it’s behind the times.

Specifically, Gates is funding a soon-to-be-public battery maker that says it can increase the distance EVs can travel on a single charge by 50%. Not only does this technology extend range, but it also improves safety and cuts the charging time of batteries to less than 15 minutes.

Next to Bill Gates, Kleiner Perkins and Khosla Ventures have already put tens of millions into that startup. The largest investor, however, is direct Tesla rival Volkswagen, which has ~$300 million in financial commitments to the company.

Of course, claims in slide decks should always be viewed with a degree of skepticism, but the technology this company is producing, solid-state lithium-ion, is widely regarded as the next major leap in electrification. We’ll have a report on that technology in the near future, so be sure to keep an eye out as we parse out the details.

This article was originally published here

Elon Musk Reveals Bombshell New Tech

Elon Musk just dropped a BOMBSHELL that could send shockwaves through the tech industry…

And deliver a death blow to some of the world’s BIGGEST companies.

Why is no one talking about it?

Because what he revealed happened behind closed doors…

At a private meeting attended by a small number of tech insiders.

Luckily, I had a man on the inside…

And in his MUST-SEE presentation, he reveals what Elon Musk talked about…

Including pictures of a breakthrough technology related to this story…

And how he predicts it will deliver MASSIVE profits to anyone who knows about it NOW.

Click here now to learn what was discussed in this closed-door meeting – and why my “inside man” thinks it could make you a fortune in profits this year.